Evandro de Azambuja
Université libre de Bruxelles
CancerSurgeryOncologyRandomized controlled trialAdverse effectHazard ratioMetastatic breast cancerChemotherapyAnthracyclineLapatinibAdjuvantAdjuvant therapyDiseaseTrastuzumabEpirubicinPopulationGynecologyBreast cancerClinical trialMedicine
283Publications
48H-index
10.8kCitations
Publications 284
Newest
#1Elisa Agostinetto (ULB: Université libre de Bruxelles)
#2Daniel Eiger (ULB: Université libre de Bruxelles)H-Index: 4
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 11 authors...
Abstract Background Immune checkpoint inhibitors (ICIs) may cause potentially life-threatening adverse events (AEs), but the risk of cardiotoxicity has not been fully investigated. It is also unknown whether ICI combinations increase cardiotoxicity compared with single ICI. We aimed to assess the cardiotoxicity of ICI in a range of tumour types. Methods This systematic review and meta-analysis was conducted according to PRISMA guidelines (PROSPERO registration number: CRD42020183524). A systemat...
Source
#1Maria Alice Franzoi (ULB: Université libre de Bruxelles)H-Index: 3
#2Daniel Eiger (ULB: Université libre de Bruxelles)H-Index: 4
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 14 authors...
BACKGROUND There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors. METHODS Pooled analysis of individual patient-level data from MONARCH 2 and 3 trials. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2) and divided into two treatment groups: abemaciclib +...
4 CitationsSource
#1Elisa Agostinetto (ULB: Université libre de Bruxelles)
#2Daniel Eiger (ULB: Université libre de Bruxelles)H-Index: 4
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 4 authors...
PURPOSE OF REVIEW Triple negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancers and it is associated with a poor prognosis. However, recent new effective treatment strategies have improved its outcomes. The aim of this review is to provide an overview on the emerging therapeutics for TNBC, describing both previously approved therapies that are currently being repurposed, as well as new target therapies that may improve patient outcomes. RECENT FINDINGS Emerging the...
Source
#1Maria Alice Franzoi (ULB: Université libre de Bruxelles)H-Index: 3
#2Rita Saúde-Conde (Instituto Português de Oncologia Francisco Gentil)
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 6 authors...
Abstract Background/methods: Although the prognosis of metastatic breast cancer (BC) has improved, some patients still develop high burden metastases or visceral crisis (VC) and polychemotherapy is commonly used in these cases. Data reporting the real effectiveness of this strategy are scanty. Therefore, the outcomes of patients with metastatic BC treated with platinum-based chemotherapy (P-ChT) at the Jules Bordet Institute during the period of January 2008 and December 2018 were retrospectivel...
Source
#1Alvaro Moreno-Aspitia (Mayo Clinic)H-Index: 26
#2Eileen M. Holmes (Dund.: University of Dundee)H-Index: 4
view all 30 authors...
AIM To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. PATIENTS AND METHODS 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy plus 1-year of trastuzumab (T), oral lapatinib (L; no longer evaluated), trastuzumab followed by lapatinib (T→L), and lapatinib + trastuzumab (L+T). The primary endpoint was disease-free survival (DFS). A secondary analysis examined DFS treatment effects by hormone receptor status, nodal status and...
Source
#1Amir Sonnenblick (Tel Aviv Sourasky Medical Center)H-Index: 4
Last. Christos Sotiriou (ULB: Université libre de Bruxelles)H-Index: 83
view all 14 authors...
The JAK/STAT3 signaling pathway may be aberrantly activated and have various and conflicting roles in breast cancer. The current study explored prognostic implications of activated STAT3 in human epidermal growth factor receptor 2 (HER2)-positive primary breast cancers in the context of a large prospective study (ALTTO). Activated STAT3 was determined by immunohistochemical analysis of STAT3 phosphorylation (Y705) performed on the primary tumors. This analysis evaluated whether patients with act...
Source
#1Elisa Agostinetto (ULB: Université libre de Bruxelles)
#2Véronique Debien (ULB: Université libre de Bruxelles)
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 6 authors...
Background HER2-positive (HER2+) breast cancer represents a heterogeneous breast cancer subtype, including both estrogen receptor (ER) positive and negative tumours. A deeper understanding of the crosstalk between ER and HER2 receptor pathways has led to the development of treatment strategies consisting of a simultaneous blockade of both signaling pathways, as a reasonable approach to prevent the onset of mechanisms of resistance. Methods This review was based on the material searched on PubMed...
Source
#1Daniel Eiger (ULB: Université libre de Bruxelles)H-Index: 4
Last. Evandro de AzambujaH-Index: 48
view all 4 authors...
Since human epidermal growth factor receptor-2 (HER2) characterization, going through clinical research and regulatory approval of HER2-targeted therapies, much has elapsed and is still unfolding. Hitherto, only breast cancer (BC) patients with HER2 immunohistochemistry 3+ or with HER2 gene fluorescence in-situ hybridization (FISH) amplification (a.k.a., HER2-positive BC) have benefited from anti-HER2 agents. In recent years, however, much of the research effort has been expanded, with positive ...
Source
#1N. ChicH-Index: 4
#2Stephen J LuenH-Index: 12
Last. Sherene LoiH-Index: 73
view all 14 authors...
Source
Source
12345678910
Close Researchers